{"transactions":[{"id":2806429,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Restricted Stock Unit","published_at":"2021-03-05T17:53:15.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":13125,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"date","element":"transactionDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"On March 3, 2021, the reporting person was granted 13,125 Restricted Stock Units (\"RSUs\") pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on January 1, 2022 and the remaining awards vesting as to 25% in substantially equal annual installments."}],"balance_after":13125,"derivative":{"underlying":"Common Stock","underlying_shares":13125},"source":{"system":"sec-edgar","filing":"0001209191-21-018326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919121018326/doc4.xml","form_type":"4"}},{"id":2806428,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-05T17:53:15.000Z","date":"2021-03-03","kind":"grant","acquired":true,"shares":78750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 3, 2021 with respect to 78,750 shares of Common Stock, with 25% vesting on January 1, 2022 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":78750,"derivative":{"exercise_price":57.71,"expiration_date":"2031-03-02","underlying":"Common Stock","underlying_shares":78750},"source":{"system":"sec-edgar","filing":"0001209191-21-018326","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919121018326/doc4.xml","form_type":"4"}},{"id":2921105,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Restricted Stock Unit (performance-based)","published_at":"2021-01-05T20:58:21.000Z","date":"2020-12-31","kind":"exercise","acquired":false,"shares":4792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"date","element":"transactionDate","label":"F4","text":"On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"shares","element":"transactionShares","label":"F4","text":"On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."}],"balance_after":0,"derivative":{"exercise_date":"2020-12-31","underlying":"Common Stock","underlying_shares":4792},"source":{"system":"sec-edgar","filing":"0001209191-21-001718","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919121001718/doc4.xml","form_type":"4"}},{"id":2921104,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Restricted Stock Unit (performance-based)","published_at":"2021-01-05T20:58:21.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":4792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"date","element":"transactionDate","label":"F4","text":"On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"shares","element":"transactionShares","label":"F4","text":"On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On May 1, 2018, the reporting person was granted 14,375 PRSUs pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. Each PRSU represents a contingent right to receive one share of the Company's common stock upon vesting, with one-third of the PRSUs vesting upon each achievement of the Performance Milestones through the calendar year 2020. On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of 4,792 PRSUs."}],"balance_after":4792,"derivative":{"exercise_date":"2020-12-31","underlying":"Common Stock","underlying_shares":4792},"source":{"system":"sec-edgar","filing":"0001209191-21-001718","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919121001718/doc4.xml","form_type":"4"}},{"id":2921103,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-05T20:58:21.000Z","date":"2020-12-31","kind":"grant","acquired":true,"shares":9583,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"On May 1, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the \"Performance Milestones\"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares."},{"field":"shares","element":"transactionShares","label":"F3","text":"On May 1, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the \"Performance Milestones\"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On May 1, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the \"Performance Milestones\"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On May 1, 2018, the reporting person was granted an option to purchase 28,750 shares of common stock pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan. The award had performance-based vesting, with one-third of the award vesting upon each achievement of three scientific and regulatory milestones through the calendar year 2020 (the \"Performance Milestones\"). On December 31, 2020, one of the Performance Milestones was achieved, resulting in the vesting of the option as to 9,583 shares."}],"balance_after":9583,"derivative":{"exercise_price":20.56,"exercise_date":"2020-12-31","expiration_date":"2028-03-20","underlying":"Common Stock","underlying_shares":9583},"source":{"system":"sec-edgar","filing":"0001209191-21-001718","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919121001718/doc4.xml","form_type":"4"}},{"id":2921102,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-05T20:58:21.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":1377,"price":55.86,"value":76919.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of 4,792 performance-based restricted stock units (\"PRSUs\") on December 31, 2020."}],"balance_after":16656,"source":{"system":"sec-edgar","filing":"0001209191-21-001718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919121001718/doc4.xml","form_type":"4"}},{"id":2921101,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-05T20:58:21.000Z","date":"2020-12-31","kind":"exercise","acquired":true,"shares":4792,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 568 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2020."}],"balance_after":18033,"source":{"system":"sec-edgar","filing":"0001209191-21-001718","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919121001718/doc4.xml","form_type":"4"}},{"id":2925810,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-01-04T21:03:39.000Z","date":"2020-12-30","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 146,875 shares as of December 30, 2020."}],"balance_after":148500,"derivative":{"exercise_price":13.48,"expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001209191-21-000584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919121000584/doc4.xml","form_type":"4"}},{"id":2925809,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Common Stock","published_at":"2021-01-04T21:03:39.000Z","date":"2020-12-30","kind":"exercise","acquired":true,"shares":1500,"price":13.48,"value":20220.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 857 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2020."}],"balance_after":12673,"source":{"system":"sec-edgar","filing":"0001209191-21-000584","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919121000584/doc4.xml","form_type":"4"}},{"id":3227999,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T17:27:16.000Z","date":"2020-03-02","kind":"grant","acquired":true,"shares":135000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on March 2, 2020 with respect to 135,000 shares of Common Stock, with 25% vesting on January 1, 2021 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":135000,"derivative":{"exercise_price":13.4,"expiration_date":"2030-03-01","underlying":"Common Stock","underlying_shares":135000},"source":{"system":"sec-edgar","filing":"0000899243-20-006973","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000089924320006973/doc4.xml","form_type":"4"}},{"id":3227998,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-04T17:27:16.000Z","date":"2020-01-03","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On January 3, 2017, the reporting person was granted an option to purchase 15,000 shares of common stock. The option vested based on the satisfaction of certain performance criteria. The performance criteria was met, resulting in the vesting of option as to 15,000 shares."}],"balance_after":15000,"derivative":{"exercise_price":13.48,"exercise_date":"2020-01-03","expiration_date":"2027-01-02","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-20-006973","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000089924320006973/doc4.xml","form_type":"4"}},{"id":3449330,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-02T16:15:15.000Z","date":"2019-08-01","kind":"grant","acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on August 1, 2019 with respect to 55,000 shares of Common Stock, with 25% vesting on August 1, 2020 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":55000,"derivative":{"exercise_price":18.09,"expiration_date":"2029-07-31","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001209191-19-044238","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919119044238/doc4.xml","form_type":"4"}},{"id":3599532,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Dev and Corp Strategy"}}],"security":"Common Stock","published_at":"2019-03-12T16:38:50.000Z","date":"2019-03-06","kind":"purchase","acquired":true,"shares":4250,"price":15.5,"value":65875.0,"ownership":{"direct":true},"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-19-018817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919119018817/doc4.xml","form_type":"4"}},{"id":3599531,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Dev and Corp Strategy"}}],"security":"Common Stock","published_at":"2019-03-12T16:38:50.000Z","date":"2019-03-06","kind":"purchase","acquired":true,"shares":3250,"price":16,"value":52000.0,"ownership":{"direct":true},"balance_after":3250,"source":{"system":"sec-edgar","filing":"0001209191-19-018817","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919119018817/doc4.xml","form_type":"4"}},{"id":3723498,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Dev and Corp Strategy"}}],"security":"Stock Option (right to buy)","published_at":"2018-12-20T16:23:47.000Z","date":"2018-12-18","kind":"grant","acquired":true,"shares":81000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on December 18, 2018 with respect to 81,000 shares of Common Stock, with 25% vesting on December 18, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":81000,"derivative":{"exercise_price":14.58,"expiration_date":"2028-12-17","underlying":"Common Stock","underlying_shares":81000},"source":{"system":"sec-edgar","filing":"0001209191-18-063663","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919118063663/doc4.xml","form_type":"4"}},{"id":3949867,"issuer":{"id":4585,"kind":"organization","name":"Intellia Therapeutics, Inc.","symbol":"NTLA"},"owners":[{"id":141736,"kind":"person","name":"SCHIERMEIER ANDREW","position":1,"cik":"0001738456","reported_name":"SCHIERMEIER ANDREW","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP, Corporate Strategy"}}],"security":"Stock Option (right to buy)","published_at":"2018-05-02T16:35:46.000Z","date":"2018-05-01","kind":"grant","acquired":true,"shares":23500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 1, 2018 with respect to 23,500 shares of Common Stock, with 25% vesting on May 1, 2019 and the remaining 75% vesting in 36 substantially equal monthly installments thereafter."}],"balance_after":23500,"derivative":{"exercise_price":20.56,"expiration_date":"2028-04-30","underlying":"Common Stock","underlying_shares":23500},"source":{"system":"sec-edgar","filing":"0001209191-18-027373","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1738456/000120919118027373/doc4.xml","form_type":"4"}}]}